-78%

est. 2Y upside i

HealthcareSeries A

Roon is a Sequoia-backed company since Arc Americas 2022.

Rank

#3409

Sector

Healthcare Technology

Est. Liquidity

~6Y

Data Quality

Data: Medium

Roon presents a risky equity opportunity due to its pre-revenue stage and unproven business model, despite a clear mission to combat medical misinformation.

Last updated: March 10, 2026

Bull (10%)+300%

Roon successfully establishes itself as the trusted, expert-vetted video health information platform, attracting a large user base and successfully implementing a subscription or B2B monetization model. This could lead to a strategic acquisition by a major health tech or media company, or a successful Series B/C round at a significantly higher valuation, reaching $272M+ (4x current valuation) within 2-3 years.

Base (45%)+50%

Roon gains moderate traction in specific health niches, building a loyal but smaller user base. Monetization efforts show early promise but struggle to scale broadly against established incumbents. The company secures additional funding at a modest step-up, reaching a valuation of $102M (1.5x current valuation) in 2-3 years, or is acquired for a slight premium.

Bear (45%)-80%

Roon struggles to differentiate sufficiently from incumbents like Google and WebMD, or fails to find a scalable and profitable business model. User acquisition costs are high, and the platform does not achieve critical mass. This leads to a down round or an inability to raise further capital, resulting in a valuation decline to $13.6M (-80% from current valuation), significantly impacting common stock value due to $22M in liquidation preferences.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Funding Intensity

33%

Investors hold $22M in liquidation preferences, meaning common stock holders may receive little or nothing in an exit at or below the current $68M valuation.

Dilution Risk

high

As an early-stage, pre-revenue company, Roon will likely require multiple additional funding rounds, leading to further dilution for existing equity holders.

Secondary Liquidity

none

Given its Series A stage and private status, there is currently no active secondary market for Roon's equity.

Questions to Ask at the Interview

Strategic questions based on Roon's data — designed to show you've done your homework.

  • 1

    “How is Roon planning to differentiate its monetization strategy from existing online health platforms, and what is the projected timeline for achieving significant revenue?”

  • 2

    “Given the strong incumbent threat from Google and WebMD, what specific strategies are in place to acquire and retain a critical mass of users, and how does the 'Roon for Doctors' platform integrate into this strategy?”

  • 3

    “With $22M in total funding and a $68M valuation, how does the company envision its next funding round, and what are the key milestones Roon aims to achieve to ensure a favorable valuation for future equity holders?”

Community

Valuation Sentiment

Our model estimates -78% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.